New! Sign up for our free email newsletter.
Science News
from research organizations

Trial shows new imaging system may cut X-ray exposure for liver cancer patients

Date:
November 26, 2014
Source:
Johns Hopkins Medicine
Summary:
Researchers report that their test of an interventional X-ray guidance device approved by the US Food and Drug Administration in 2013 has the potential to reduce the radiation exposure of patients undergoing intra-arterial therapy for liver cancer.
Share:
FULL STORY

Johns Hopkins researchers report that their test of an interventional X-ray guidance device approved by the U.S. Food and Drug Administration in 2013 has the potential to reduce the radiation exposure of patients undergoing intra-arterial therapy (IAT) for liver cancer.

In a report prepared for presentation Dec. 3 at the 100th annual meeting of the Radiological Society of North America in Chicago (abstract #SSM24-02), the researchers described the results of a clinical trial of the imaging system AlluraClarity, made by Philips Healthcare, on 50 patients with liver cancer. Its use reduced radiation exposure up to 80 percent, compared with exposure from a standard imaging X-ray platform used in IAT, while producing images just as clear as the standard system, says Jean-Francois Geschwind, M.D., a professor in the Russell H. Morgan Department of Radiology and Radiological Science in the Johns Hopkins University School of Medicine and its Kimmel Cancer Center.

Geschwind says if further studies continue to affirm his team's findings, the platform may be especially useful for patients who need repeat therapy; children, who are especially vulnerable to radiation; and physicians who routinely use procedures such as IAT and are exposed to radiation.

During IAT, a physician inserts a thin, flexible tube directly into a blood vessel feeding a tumor, using that pathway to deliver chemotherapy or other drugs. X-ray imaging is used during the procedure to visualize the patient's blood vessels and to guide both the catheter's placement and drug delivery.

Geschwind and his colleagues compared the radiation exposure of 25 patients with liver cancer treated with IAT using the AlluraClarity platform to the exposure of 25 additional patients with liver cancer treated with IAT using Philips' previous X-ray imaging platform, called Allura.

Lowering the radiation power on standard X-ray imaging platforms can reduce the exposure, but without special image processing, the amount of image noise increases and physicians are unable to see small structures needed for good treatment, says Ruediger Schernthaner, M.D., a postdoctoral research fellow in vascular and interventional radiology at The Johns Hopkins Hospital. "You can compare this to an image taken with your cell phone in the evening without a flash," he says.

The AlluraClarity platform uses a series of real-time image processing algorithms to achieve high quality images at a lower radiation power, Schernthaner says.


Story Source:

Materials provided by Johns Hopkins Medicine. Note: Content may be edited for style and length.


Cite This Page:

Johns Hopkins Medicine. "Trial shows new imaging system may cut X-ray exposure for liver cancer patients." ScienceDaily. ScienceDaily, 26 November 2014. <www.sciencedaily.com/releases/2014/11/141126171430.htm>.
Johns Hopkins Medicine. (2014, November 26). Trial shows new imaging system may cut X-ray exposure for liver cancer patients. ScienceDaily. Retrieved April 13, 2024 from www.sciencedaily.com/releases/2014/11/141126171430.htm
Johns Hopkins Medicine. "Trial shows new imaging system may cut X-ray exposure for liver cancer patients." ScienceDaily. www.sciencedaily.com/releases/2014/11/141126171430.htm (accessed April 13, 2024).

Explore More

from ScienceDaily

RELATED STORIES